U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D. C.  20549  FORM 10-Q/A Amendment #1 (Mark One) [X] QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF1934  For the fiscal quarter ended_________March 31, 2010_______________  [   ]  TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE EXCHANGE ACT For the transition period from                      
                   to  VYCOR MEDICAL, INC. (Exact name of small business issuer as specified in its charter)  Delaware333-14978220-3369218(State of Incorporation)(Commission File Number)(IRS Employer Identification No.)  80 Orville Drive, Suite 100, Bohemia, New York 11716 
(Address of principal executive offices) (Zip code)  Issuers telephone number: (631) 244 1435Securities registered under Section 12(g) of the Exchange Act:  Indicate by check mark whether the registrant (1) has filed all reports required to be filed by
Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter
period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for
the past 90 days. Yes þ    No o  Indicate by check mark whether the registrant has submitted electronically and posted on its corporate
Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T during
the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).
Yes o    No o  Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a
non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer”
and “smaller reporting company” in Rule 12b-2 of the Exchange Act.  Large accelerated filer oAccelerated filer oNon-accelerated filer o   (Do not check if a smaller reporting company)Smaller reporting company þ  Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes o   No þ  There were 675,357,950 shares outstanding of registrant’s common stock, par value $.0001 per share, as of July 31, 2010. Transitional Small Business Disclosure Format (check one):     Yes o   No þ   EXPLANATORY NOTE
Vycor Medical, Inc. (the “Company) is filing this Amendment No. 1
(the “Amendment”) to its Quarterly Report on Form 10-Q for the quarter ended March 31, 2010, which was originally filed with
the Securities and Exchange Commission (the Commission) on May 24, 2010 (the Original Filing), for the purpose
of amending the original Exhibits 31.1 and 31.2 to comply with Item 601(b)(31) of Regulation S-K.
Except as described above, no other changes have been made to the Original
Filing.  The Original Filing continues to speak of the dates described in the Original Filing, and we have not updated the
disclosures contained therein to reflect any events that occurred subsequent to such dates.  Accordingly, this Amendment should be
read in conjunction with the Companys filings made with the Commission subsequent to the filing of the Original Filing, as information
in such filings may update or supersede certain information contained in this Amendment.




TABLE OF CONTENTS

PART II

Item 6.
ExhibitsSIGNATURESEXHIBIT INDEX



PARTII
ITEM 6. EXHIBITS

Index to Exhibits

31.1Certification of Chief Financial Officer under Rule 13(a) - 14(a) of the Exchange Act.31.2Certification of Chief Executive Officer under Rule 13(a) - 14(a) of the Exchange Act.

SIGNATURES

In accordance with Section 13 or 15(d) of the Exchange Act, the registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized, on October 19, 2010.

VYCOR MEDICAL, INC.By:/s/ Kenneth T. CovielloKenneth T. CovielloChief Executive Officer

EXHIBIT INDEX

31.1Certification of Chief Financial Officer under Rule 13(a) - 14(a) of the Exchange Act.31.2Certification of Chief Executive Officer under Rule 13(a) - 14(a) of the Exchange Act.